세계 양성자 치료는 2024년 7억 6,834만 달러에서 2032년 14억 2,214만 달러로 성장하여 예측 기간(2025-2032년) 동안 연평균 8.00%의 성장률을 보일 것으로 예상됩니다. 미국 국립암 연구소는 미국에서는 623,405명이 전이성 암을 앓고 있으며, 2025년에는 693,453명으로 증가할 것으로 예측했습니다. 따라서 진행암에 대한 효과적인 치료에 대한 요구가 높아지고 있습니다. 방사선 치료와 달리 양성자 치료는 부작용이 적습니다. 이는 방사선 요법이 표적 부위 근방의 조직을 손상하는 반면 양성자 치료는 정상 세포를 손상시키지 않고 암세포만을 표적으로 하기 때문입니다. 양성자 치료는 부작용이 적기 때문에 치료법으로 인기를 얻고 있습니다. 따라서 양성자 치료는 매우 효과적이며 건강한 조직에 미치는 영향도 적기 때문에 수요와 가치가 계속 상승할 것으로 보입니다.
그 밖의 요인으로는 부작용이 적고 유효율이 높은 치료법에 대한 수요가 높아지고, 양성자 치료 센터의 급속한 확대, 펜슬 빔 스캐닝 등 치료 효율을 높이는 기술 개발, 보험 적용 확대, 암 대책에 있어서의 정부의 대처 증가, 종양 미세 환경을 보다 잘 이해해 효과적인 치료법의 이용 가능성을 높이기 위한 암 생물학 연구의 중요성이 커지고 있습니다.
세계적으로 양성자 치료 센터가 증가하고 접근과 용량이 향상되고 있는 것도 시장 성장을 뒷받침하고 있습니다. 컴팩트하고 비용 효율적인 양성자료 치료 시스템의 도입이 진행됨에 따라, 이 선진 기술을 채용하는 병원이나 암 치료 시설이 늘어나고 있습니다. 2024년 5월 IBA(Ion Beam Applications SA)는 코네티컷 양성자 치료 센터(예일 뉴 헤이븐 헬스, 하트포드 헬스케어, 양성자 인터내셔널의 파트너십)와 Proteus ONE 양성자 치료 시스템 설치 계약을 체결했습니다. 이 계약은 다년간의 보수 계약이며, 환자는 2026년 봄부터 치료를 받을 예정입니다. 이 계약은 환자가 현지로 이동할 때의 부담을 줄이면서 치료 시간을 엄수하는 것을 목적으로 합니다. 신흥 시장의 센터는 양성자 치료에 대한 환자의 신뢰를 높이는데 도움이 되는 인지도를 만들어 내고, 정밀 기반의 암 치료 솔루션에 대한 세계의 요구의 고조에 대응합니다.
모든 부문은 해당 지역 및 국가에서 제공됩니다.
위에 언급된 회사들은 시장 점유율 순위와 관련이 없으며, 조사 과정에서 얻은 정보에 따라 변경될 수 있습니다.
Global proton therapy is projected to witness a CAGR of 8.00% during the forecast period 2025-2032, growing from USD 768.34 million in 2024 to USD 1422.14 million in 2032. The rising prevalence of cancer is promoting the growth of the market; the National Cancer Institute has stated that 623,405 people in the United States are living with metastatic cancer, and this is expected to rise to 693,453 by 2025. Therefore, there is a growing need for effective treatment for advanced-stage cancer. Unlike radiation therapy, proton therapy produces fewer side effects. This is because radiation therapy damages the tissues near the targeted area, while proton therapy only targets cancerous cells without damaging the normal cells. Proton therapy has fewer side effects and, hence, has gained popularity for treatment. Therefore, demand and value for proton therapy will keep rising because the treatment is quite effective and has a minimal impact on healthy tissues.
Other factors include higher demand for treatments that have a better effectiveness rate with fewer side effects, the rapid expansion of proton therapy centers, technological developments that enhance treatment efficiency, such as pencil beam scanning, increased insurance coverage, increasing government initiatives in cancer control, and the growing importance given to research on cancer biology to understand the tumor microenvironment better and boost the availability of effective treatments.
The growing number of proton therapy centers worldwide with improved access and capacity enhances market growth. As compact and cost-effective proton therapy systems are increasingly installed, more hospitals and cancer treatment facilities are adopting this advanced technology. In May 2024, IBA (Ion Beam Applications S.A.) signed a contract with Connecticut Proton Therapy Center (a Partnership with Yale New Haven Health, Hartford HealthCare, and Proton International) to install a Proteus ONE proton therapy system. The agreement is a multiyear maintenance deal, and patients are expected to receive treatment in spring 2026. The agreement is a multiyear maintenance deal, and patients are expected to receive treatment in spring 2026. It is designed to alleviate burdens associated with patients traveling to sites while being on time with treatments. Centers in emerging markets create an awareness that helps increase patients' confidence in proton therapy, hence catering to the growing global need for precision-based cancer treatment solutions.
Growing Government Initiatives Boost Market Demand
Proton therapy is becoming increasingly popular due to increasing government efforts to develop more advanced cancer treatment facilities and healthcare infrastructure. Governments worldwide are investing in advanced medical devices and technologies to improve cancer care, thereby driving the adoption of proton therapy. In July 2024, Romania's Ministry of Health invested USD 123.276 million (EUR 120 million) in a project to build the country's first proton therapy center, thereby improving its healthcare infrastructure. This center will offer advanced cancer treatment, minimizing patients' need to go abroad and boosting demand and market growth for proton therapy in Romania. Moreover, market growth is also bolstering as more people become aware of the advantages of proton therapy over traditional radiation therapy, which includes higher precision in targeting tumors and fewer side effects. Establishing specialized healthcare centers and public-private partnerships further improves access to this cutting-edge therapy. Also, favorable policies, research funding, and infrastructure updates in emerging nations are accelerating the establishment of proton therapy centers, meeting the rising demand for innovative cancer treatment solutions.
Rising Research Activities Support Market Expansion
The proton therapy market is rapidly growing, driven by increased research activities emphasizing its clinical advantages and diversifying its uses. A study in proton therapy presented in 2024 at the American Society of Clinical Oncology (ASCO) annual meeting highlighted proton therapy as a potential new standard-of-care treatment for controlling head and neck malignancies. This study found that proton therapy provides superior precision in targeting tumors while protecting healthy surrounding tissues, lowering side effects, and improving patient quality of life. Such research findings provide persuasive evidence of proton therapy's superiority over traditional radiation therapies, and this evidence fueled the interest of healthcare providers as well as researchers. Such research is driving major investments in proton therapy technologies and infrastructure. As more clinical data emerges, the growing acknowledgment of proton therapy's benefits speeds up its adoption, building a strong foundation for sustained growth in the worldwide cancer domain.
Single-Room Systems; the Fastest Growing Segment in the Market
The single-room proton therapy system segment is expected to grow significantly during the forecast period, owing to its cost-effectiveness, compact design, and rising need for easily accessible cancer treatment options. Single-room systems, as compared to multi-room systems, require less space and lesser initial investments, making them an appealing option for smaller healthcare facilities and growing markets. There has been a noticeable increase in the installation of single-room systems, especially for cancer treatment, which supports this trend. Many cancer centers are currently using these systems to accurately treat localized tumors while lowering infrastructure costs. Moreover, the compact design of these single-room systems also facilitates faster installation and operational readiness, which helps medical professionals to better handle increasing cancer loads. In June 2024, the MEVION S250-FIT Proton Therapy System, a compact single-room system, was installed at Carol G. Simon Cancer Center (at Morristown Medical Center, U.S.). This new system, which will be utilized for service in 2025, will improve radiation oncology treatments and accelerate the growth of the single-room systems segment. Because of its clinical effectiveness, affordability, and scalability, positioning single-room systems plays a crucial role in the market expansion of proton therapy.
North America Dominates the Global Proton Therapy Market Share
North America is currently dominating the proton therapy market and holds a significant share because of various key factors contributing to its solid position in the market. The region has a well-established healthcare system, with advanced equipment to integrate new technologies such as proton therapy. The geriatric population in the U.S. has increased, leading to higher cases of cancer, thereby increasing the demand for advanced therapies. These supportive reimbursement policies of the U.S. healthcare system have relieved the financial barrier for patients and practitioners in adopting proton therapy. Continued growth in the number of centers providing proton therapy across the United States is due to private investment and government programs. These centers provide increased access to high-precision cancer treatment. For instance, in September 2024, UC Regents approved the UCSF cancer treatment center, including a proton therapy center, research space, life sciences incubator, and clinics in San Francisco's Dogpatch Power Station. The UCSF Life Sciences Building will provide advanced cancer care and innovative research facilities. Moreover, awareness among healthcare professionals and patients about the benefits of proton therapy is increased, which adds to the region's dominant position in the global market.
Future Market Scenario (2025 - 2032F)
The proton therapy market is expected to see substantial growth in the coming years with advancements in technology, increasing investment, and an increased awareness level worldwide. Another reason for this growth is the growing developments in compact proton therapy centers that need less space and have lower costs than multi-room systems. This compact solution brings proton therapy to the forefront of smaller health facilities and new markets. Investment in private and public sectors drives innovation, resulting in more efficient and cost-effective systems and enhanced treatment options. In July 2024, Australia invested USD 721 million in the Queensland Cancer Centre, which is expected to open in 2028. The center will offer proton beam therapy and other advanced treatments that increase the precision of cancer treatment. This is expected to propel the growth of the proton therapy market. Moreover, expanding cancer care institutes also supports market growth. For instance, BayCare Cancer Institute will open a 'compact' proton therapy center in 2025. Advanced technology allows for acceleration in construction, as the machines do not take up as much space as traditional ones. This will fuel further market growth because proton therapy is easier to access and has a reduced cost.
Furthermore, with a growing incidence of cancer and a desire for more precise, minimally invasive treatments, the market continues to expand rapidly. Proton therapy is bound to be transformative in the treatment of cancer going forward as infrastructural development and further clinical evidence will establish its superiority.
Key Players Landscape and Outlook
Key market players in the proton therapy market are strengthening their position through continuous technological innovation, collaborations, and geographic expansion. For instance, they invest in compact, cost-effective systems and optimize treatment precision. Increasing partnerships with healthcare service providers and research organizations accelerate adoption and market growth.
In January 2025, IBA (Ion Beam Applications SA) signed a deal with AIG Hospitals under which the latter committed to spend USD 96 million (Rs 800 crore) for equipping a Proteus ONE Proton Therapy System. This sophisticated acquisition, involving DynamicARC technology, will elevate IBA as a market leader in proton therapy equipment and service supply. It emphasizes IBA's commitment to developing cancer treatment technology and extending its international reach in the healthcare market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.